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Abstract
Background: Beta-herpesviruses are common opportunistic pathogens that cause morbidity after liver
transplantation (LT).
Methods: Objective of the study was to evaluate the prevalence and correlation of herpesviruses in bile, blood and
liver tissue and to investigate their association with biliary complications and retransplantation (re-LT) free survival
after LT.
The study design is a single-center case-control study. We performed quantative polymerase chain reaction (qPCR)
for herpesvirus 1–8 DNA in bile, blood and liver tissue of 73 patients after first LT and analyzed their clinical courses
retrospectively.
Results: The median follow-up was 48 months (range 2–102), during which a total of 16 patients underwent re-LT
and 11 patients died. Of the patients, 46.5% received valganciclovir prophylaxis at the time of bile sample
acquisition. Cytomegalovirus (CMV) (18.3%), human herpesvirus 6 (HHV-6) (34.2%), human herpesvirus 7 (HHV-7)
(20.5%) and Epstein-Barr virus (EBV) (16.4%) were highly prevalent in bile after LT, while herpes simpex virus 1 and 2
(HSV-1, HSV-2), varicella-zoster virus (VZV) and human herpesvirus 8 (HHV-8) were not or rarely detected in bile.
Valganciclovir prophylaxis did not reduce the prevalence of HHV-6 and HHV-7 in bile, but it did reduce the
presence of CMV and EBV. The presence of HHV-6 in bile was associated with non-anastomotic biliary strictures
(NAS) and acute cellular rejection (ACR).
Conclusions: CMV, EBV, HHV-6 and HHV-7 are more prevalent in biliary fluid than in liver biopsy or blood serum
after LT. HHV-6 and HHV-7 might be associated with biliary complications after LT. Biliary fluids might be an
attractive target for routine herpesvirus detection.
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Background
Liver transplantation (LT) is to date the only curative
option for patients with end-stage liver disease. Liver
transplantation requires lifelong immunosuppression to
prevent allograft rejection and subsequent graft failure.
Immunosuppression predisposes solid organ recipients
to various opportunistic infections. The role of many of
these opportunistic pathogens in the development of
complications after LT is unknown. Human herpesvi-
ruses (HHV) 1–8 are enveloped, double-stranded DNA
and human host specific viruses that proliferate in lym-
phocytes and neuronal or epidermal cells. They can
persist lifelong in the host and reactivate under circum-
stances of immunosuppression. Active disease can be
detected by polymerase chain reaction (PCR) of HHV
1–8 DNA [1]. The incidence of Cytomegalovirus
(CMV), HHV-6 and HHV-7 in blood after LT has been
reported as high as 70, 33 and 42%, respectively [2].
CMV is the most common infectious pathogen after LT
[3] and can infect various organs, including the allograft
itself. CMV in bile has been associated with early graft
loss and biliary complications after LT [4]. HHV-6 and
HHV-7, together with CMV (HHV-5), comprise the
group of beta-herpesviruses. Human herpesvirus 6 has
been linked to hepatitis post LT, but most HHV-6 infec-
tions after LT are asymptomatic [5, 6]. The presence of
HHV-6 and HHV-7 viremia in blood after LT has incon-
sistently been linked to reduced graft survival. However,
detecting HHV-6 DNA in liver biopsies has been associ-
ated with graft hepatitis and reduced graft survival [7–
9]. Epstein-Barr virus (EBV) and CMV detection in liver
biopsies had no effect on overall survival after LT [7]. To
prevent the reactivation of CMV after LT, patients re-
ceive valganciclovir chemoprophylaxis for three to 6
months after LT [10]. For HHV-6 and -7, there are no
recommendations for prevention. In vitro, HHV-6 and
HHV-7 are less susceptible to ganciclovir than CMV
[11]. The objective of this study was to examine the as-
sociation between herpesviruses in different body fluids
and tissues after LT and to elucidate their role in graft
complications after LT.
Methods
Study population
In this single-center case-control study, patients were
selected retrospectively out of all adult patients who
underwent a first liver transplantation at the University
Hospital Heidelberg between January 2007 and July
2015, for which period bile samples were available in our
biobank (n = 215). Exclusion criteria were death within
30 days after transplantation, risk factors for ischemic
bile duct injury such as hepatic artery stenosis, portal vein
stenosis or portal vein thrombosis (n = 84), insufficient
sample volume (n = 53) and primary hepaticojejunostomy
(n = 5). Of the remaining 73 patients, we included bile
samples for 37 patients with NAS, 20 patients with AS
and 16 without stricture (Fig. 1). 19 patients had devel-
oped acute cellular rejection after LT of which 13 were di-
agnosed before and 6 after ERC.
Sample acquisition
Bile samples were retrieved from ERC examinations, im-
mediately frozen and stored at a temperature of − 80 °C.
Indications for ERC in all patients were abnormal liver
laboratory values. Indications for liver biopsies were sus-
pected allograft rejection or infection. Samples were
formalin-fixed, paraffin-embedded and stored appropri-
ately. Blood samples were taken routinely for check-up
or if clinically indicated and stored at − 20 °C.
Immunosuppressive and chemoprophylactic regime
All patients received corticosteroids for 6months after
transplantation. Additionally, a calcineurin inhibitor (CNI)
(ciclosporin or tacrolimus) was administered, beginning
within the first days after transplantation. Mycophenolate
(MMF) was either started directly after transplantation (de
novo), or after 21 days (delayed). Infectious complications
led to discontinuation of MMF, according to internal clin-
ical guidelines. Prophylaxis for CMV infection with val-
ganciclovir was administered to all patients within the first
3 to 6months after transplantation at a dose of 900mg
once daily (both CMV IgG seropositive donor/recipient
matches did not receive CMV prophylaxis).
Transplant allocation criteria
All patients were transplanted within the Eurotransplant
allocation system in Germany [12]. Patients were trans-
planted according to the model of end-stage liver disease
(MELD) score, which is based on the recipient’s kidney
function, coagulation time and serum bilirubin and
ranges from 6 to 40 [13]. Patients transplanted for hepa-
tocellular carcinoma were granted an exceptional MELD
score (eMELD) in which the allocation is based on wait-
ing time [14].
Clinical follow-up
The clinical records of the patients were reviewed in our
electronic patient database (i.s.h. med, SAP, Germany).
We recorded demographic data, underlying diseases and
the reasons for transplantation, immunosuppressive regi-
men and antiviral prophylaxis, infectious complications
such as herpesvirus infections, biliary complications, in-
cidence of acute or chronic graft rejection, information
on graft, donor and recipient hepatitis- and CMV-status
and recipient post- and perioperative values. All patients
were followed until death or retransplantation or until
October 1, 2015.
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Detection of herpesvirus-DNA in bile, blood and liver
tissue
DNA extraction. Herpesvirus-DNA was extracted from
400 μl of bile and 200 μl of serum using QIAamp DNA
blood mini-kit (Qiagen, Germany). To extract DNA from
the formalin-fixed paraffin-embedded liver biopsies, the
QIAamp DNA FFPE tissue kit (Qiagen, Germany) was
used. Both serum and bile samples were stored at − 80 °C,
and extracted DNA was temporarily stored at − 20 °C.
The DNA concentration after extraction was measured
with a Colibri microvolume spectrometer (Titertek-Bert-
hold, Germany).
Quantitative real time polymerase chain reaction (qPCR).
Virus-specific r-gene quantification kits (Biomerieux,
France) were used to prepare the extracted DNA for quan-
tification. The kit contains an internal control that was
added to the samples before DNA extraction to monitor
the extraction process and the presence of amplification in-
hibitors. Appropriate negative controls were performed to
check for contamination along the extraction and amplifi-
cation process. Quantification standards were available for
HHV 1–6 allowing the measurement of the viral DNA
load. The detection of HHV-7 was qualitative, and the
HHV-7 viral count could not be quantified. PCR was per-
formed using the LightCycler 480 (Roche Diagnostics,
Switzerland).
Statistical analysis
Descriptive statistics were used to characterize patients’
demographics and clinical variables. Continuous variables
are expressed as mean values with standard deviation (SD),
non-normally distributed variables as median values with
range and categorical variables as number and percent. A
chi-square test was used to compare the frequency of differ-
ences in patient characteristics, complications and medical
regimens according to herpesvirus detection in bile. Statis-
tical data was analyzed using SPSS (SPSS 22.0 Inc., USA).
Results
Total population
The clinical baseline characteristics of LT subjects are
summarized in Table 1.
Fig. 1 Flowchart of patients’ inclusion in the analysis. AS- anastomotic stricture, LT- liver transplantation, NAS – non-anastomotic stricture
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The median follow-up was 48months (range 2–102)
(Table 1). A total of 16 patients underwent re-LT at a
median time of 11 months (range 1–42), and 11 patients
died during follow-up after a median time of 15.2
months (range 7–37), with follow-up terminating at the
combined endpoint of re-LT or death. The average age
of LT recipients was 56 (range 30–69) years. Recipients
were predominantly male (79.5%), and the most frequent
indication for LT was alcoholic cirrhosis (34.5%). Donors
were slightly older with a mean age of 67 (range 21–88)
years, while gender was evenly distributed (48.6% fe-
male). The ERC from which bile was retrieved occurred
at a median of 3.4 months (range 0.3–73) after LT. At
time of ERC, 46.5% of patients were receiving valganci-
clovir as cytomegalovirus prophylaxis (900 mg per day).
All patients received immunosuppression at time of
ERC, and all but two patients received calcineurin inhib-
itors (CNI) de novo (69.9% ciclosporin, 30.1% tacroli-
mus), while 83.6% received additional mycophenolate
mofetil. Neither the time between LT and ERC nor the
immunosuppressive regimen at ERC significantly influ-
enced the rate of herpesvirus positivity in bile.
We tested ERC bile samples for herpesvirus 1–8. For
42 patients concordant serum samples were available
(median time of 8 days before or after ERC, n = 42). For
beta-herpesviruses (CMV, HHV-6, HHV-7), we also
tested available liver biopsies (median time of 38 days
before or after ERC, n = 53). Rates of herpesvirus posi-
tivity are shown in Table 2. HSV-1 and HSV-2 were
rarely detected in bile (4.1 and 0%, respectively), while
there was a significant rate of detection in serum for at
least HSV-1 (14.3%). Varicella-zoster virus appeared to
be rare after LT in serum (0%) and bile (2.4%), with only
a single positive bile sample. EBV was often detected in
bile (16.4%) and serum samples (9.5%). Cytomegalovirus
is a pathogen known to be relevant after LT. It was sig-
nificantly more prevalent in bile (18.3%) than in serum
samples (2.4%) or liver tissue (0%); this finding has been
described before [4]. HHV-6 was highly prevalent in bile
(34.2%) and liver biopsies (15.1%) but was rarely found
in serum (2.4%). The DNA copy number in bile was ra-
ther low, with a median copy number of 12.6 copies/ml
in HHV-6 positive patients whereas four patients had
biliary HHV-6 DNA titers > 1000 copies/ml. The median
HHV-6 copy number in liver biopsy was 20 copies/ml
among those patients with amplifiable HHV-6 DNA.
Only one patient in the liver biopsy group had a high
copy number, that was over 1000 copies/ml. Liver biopsy
and bile HHV-6 DNA copy number did not correlate
significantly (Pearson correlation r = − 0.026, p = 0.87).
HHV-7 was also highly prevalent in bile samples (20.5%)
but was not detected in serum (0%) and rarely in liver
biopsy (3.8%) samples. HHV-6 and HHV-7 in bile corre-
lated significantly (Pearson correlation r = 0.28, p = 0.02)
Table 1 Characteristics of patients who underwent LT. Data is
given as mean (± SD), median (range) or number (%), as
appropriate
Number of patients 73
Gender recipient, female 15 (20.5%)
Gender donor, female 36 (49.3%)
Recipient age, years, (median, range) 56 (30–69)
Donor age, years, (median, range) 67 (21–88)
Follow-up, months, (median, range) 48 (2–102)
Child-Turcotte-Pugh score (A/B/C) at LT, n 25/16/31
Valganciclovir prophylaxis at time of ERC 34 (47.1%)
Time of ERC, months since LT, (median, range) 3.4 (0.3–73)
Lab/eMELD at LT (mean ± SD) 27.0 ± 8.7
Cold ischemia time, hours (mean ± SD) 10.0 ± 2,64
Indication
Alcoholic cirrhosis 23 (31.5%)
Hepatitis B 2 (2.7%)
Hepatitis C 11 (15.1%)
HCC 15 (20.5%)
PSC 2 (2.7%)
Cryptogenic 7 (9.6%)
Other 13 (17.8%)
Death during follow-up 11 (15.1%)
Retransplantation 16 (21.9%)
Ciclosporin de novo 51 (69.9%)
Tacrolimus de novo 20 (27.4%)
Mycophenolate mofetil 61 (83.6%)
Anastomotic stricture 34 (46.6%)
Non-anastomotic stricture 37 (50.7%)
Acute rejection 19 (26.0%)
de novo: administered directly after LT; eMELD exceptional model of end-stage
liver disease, ERC endoscopic retrograde cholangiopancreatography, HHC
hepatocellular carcinoma, LT liver transplantation, labMELD laboratory model
of end-stage liver disease, PSC primary sclerosing cholangitis
Table 2 Herpesvirus prevalence after liver transplantation
Bile Serum Liver Biopsy
HSV-1 3/73 (4.1%) 6/42 (14.3%)
HSV-2 0/73 (0%) 1/42 (2.4%)
VZV 1/72 (1.4%) 0/42 (0%)
EBV 12/73 (16.4%) 4/42 (9.5%)
CMV 13/71 (18.3%) 1/42 (2.4%) 0/51 (0%)
HHV-6 25/73 (34.2%) 1/42 (2.4%) 8/53 (15.1%)
HHV-7 15/73 (20.5%) 0/42 (0%) 2/53 (3.8%)
HHV-8 1/64 (1.6%)
CMV cytomegalovirus, EBV Epstein-Barr virus, HHV human herpesvirus, HSV
herpes simplex virus, VZV varicella-zoster virus
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. HHV-6 reactivation due to HHV-7 infection has been
described previously [15].
Of the 53 patients where HHV-6 was tested in both
bile and biopsy, 29/53 (54.7%) tested concordantly nega-
tive, while 4/53 (7.5%) tested concordantly positive, 16/
53 (30.2%) tested positive in bile but not in biopsy and
4/53 tested positive in biopsy but not in bile (7.5%)
(Table 3). In chi-square test bile and biopsy positivity for
HHV-6 were not significantly associated (p = 0.35), but
those that tested concordantly positive where taken on
significantly closer timepoints (median time between bile
sample and biopsy was 3 days in concordantly positive
bile and biopsy samples vs. median time of 21 days in
non-concordant bile and biopsy samples).
We correlated HHV-6 with baseline characteristics
and compared the prevalence of HHV-6 positivity ac-
cording to complications after liver transplantation. The
labMELD score at the time of transplantation was sig-
nificantly higher patients positive for HHV-6 in bile
(16.4 vs. 22.5, p = 0.02, Table 4), while the eMELD score
(36 patients) was similar in HHV-6 in bile positive and
negative patients (27.6 vs. 27.3, Table 4).
HHV-6 positivity in bile was also associated with the
occurrence of allograft complications after LT. Non-
anastomotic strictures (NAS) of the bile duct (41.7% vs.
68.0%, p = 0.03, Table 4) and acute cellular rejection of
the liver graft (16.6% vs. 44.0%, p = 0.01, Table 4) were
significantly more common in patients with HHV-6
positivity in bile. Patients positive for HHV-6 in bile
were significantly more likely to also be positive for
HHV-7 in bile (12.5% HHV-7 pos. in HHV-6 neg. vs.
36.0% HHV-7 pos. in HHV-6 neg., p = 0.02, Table 4).
Surprisingly, HHV-6 positivity in bile did not correlate
with HHV-6 positivity in serum samples or liver biopsy
(Table 4). In addition, for the other herpesviruses, no
correlation was observed between biliary positivity and
biopsy or serum positivity (data not shown).
We assessed whether our patients had received valgan-
ciclovir as CMV prophylaxis at time of ERC. Valganci-
clovir was routinely administered for 6 months after LT
to prevent CMV reactivation in the liver allograft. Val-
ganciclovir prophylaxis did reduce the incidence of
CMV positivity in bile (9.1% vs. 27.8%, p = 0.04, Table 5),
but valganciclovir prophylaxis had no effect on the rate
of HHV-6 (38.2% vs. 27%, p = 0.25, Table 5) or HHV-7-
positivity in bile (17.6% vs. 18.9%, p = 0.9, Table 5). The
rate of EBV-positivity in bile (8.9% vs. 24.3%, p = 0.07,
Table 5) was numerically reduced but did not reach stat-
istical significance.
Patients that tested HHV-6 positive in bile were nu-
merically more likely to die or undergo re-LT after ERC.
Median survival after ERC for HHV-6 in bile positive
versus HHV-6 in bile negative patients was 36.7 vs 86.7
months respectively (log-rank p = 0.01, Fig. 2). There
was no statistically significant difference noted for any
other herpesvirus (Fig. 2). In univariate cox proportional
hazard model HHV-6 in bile was negatively associated
with retransplantation free survival (hazard ratio 2.72,
p = 0.01). We included all know risk factors in the ana-
lysis and included them in a step up approach, when
p < 0.1. This led to the inclusion of time from LT to
ERC, NAS, valganciclovir at ERC and HHV-7 in bile. In
multivariate analysis HHV-6 in bile lost its significant
negative association with retransplantation free survival
(hazard ratio 2.15, p = 0.07), but remained the strongest
risk factor for retransplantation or death among the in-
cluded (Table 6).
Discussion
Biliary fluids can routinely be assessed after ERC but are
rarely subject to scientific investigation. This is the first
single-center case-control study to investigate herpes-
virus 1–8 prevalence in human bile samples and its asso-
ciation with biliary complications after LT. We found a
high prevalence of CMV, HHV-6 and HHV-7 in biliary
fluids in LT patients both with and without biliary com-
plications. The rate of positivity of HHV-6 correlated
with poor re-LT-free survival after ERC. The persistence
of beta-herpesviruses in epithelia after LT has been de-
scribed frequently [16]. Cytomegalovirus in bile has
already been implicated in biliary lesion formation after
LT, but its significance remains controversial [4, 17, 18].
Interestingly, in our study, the rates of detection of
CMV, HHV-6 and HHV-7 in bile have been considerably
higher than in serum or liver biopsies (Table 2). In bile
we found the highest prevalence for HHV-6 (34.2%) and
HHV-7 (20.5%) followed by CMV (18.3%) and EBV
(16.4%) (Table 2). Presence of HHV-6 and HHV-7 often
coincided possibly due to viral coactivation, as 9/15 pa-
tients positive for HHV-7 in bile also tested positive for
HHV-6 [19]. We found that patients with NAS and ACR
were much more likely to test positive for HHV-6 and
HHV-7 in bile than patients of the control group (Table
4). Interestingly, neither HHV-6 nor HHV-7 in liver bi-
opsy or serum were associated with biliary complications
after LT. In Kaplan-Meier analysis HHV-6 was signifi-
cantly associated with death and retransplantation after
ERC. This significance was lost however in multivariate
Table 3 Concordance of HHV-6 positivity in bile and liver
biopsy
HHV-6 detection Bile
neg. pos. Total
Biopsy neg. 29 16 45
pos. 4 4 8
Total 33 20 53
Chi-square = 0.35
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cox proportional hazard analysis after controlling for
known risk factors such as type of stricture in the multi-
variate analysis (Fig. 2 and Table 6), however HHV-6 in
bile remained the strongest risk factor for decreased re-
LT free survival among the included. If HHV-6 in bile is
causally related to biliary strictures and thus graft sur-
vival or a mere bystander of damage of the biliary epi-
thelium remains to be determined. We are not the first
group to report the relation of HHV-6 and decreased
graft survival. In a cohort of pediatric LT recipients
chromosomally integrated HHV-6 DNA was associated
with worse graft survival [20]. HHV-6 has also been as-
sociated with worse LT graft survival in an adult popula-
tion after diagnosis of graft hepatitis with higher
intrahepatic HHV-6 amplification levels [7]. The
mechanism for this association remains unclear. How-
ever HHV-6 has been described to exert immunomodu-
latory effects such as increased secretion of interferon
gamma, tumor-necrosis factor alpha or CCL5 [21–24].
HHV-6 has also been implicated in numerous auto-
immune diseases such as multiple sclerosis, connective
tissue disorders or autoimmune thyroiditis in part
through molecular mimicry [25–29]. HHV-6 could thus
exert immunomodulatory effects in the liver allograft
leading to a host versus graft reaction leading to further
damage of the biliary ducts.
The preexisting biliary damage of the donor organ at
time of transplantation has been shown to predict subse-
quent risk for biliary complications [30]. We therefore
assessed labMELD and cold ischemia time as established
Table 4 Characteristics of patients according to HHV-6 positivity in bile. Comparison of patients based on the main primary
outcome parameter of retransplantation-free survival. Data is given as mean (± SD), median (range) or number (%), as appropriate
HHV-6 negative, n = 48 (65.7%) HHV-6 positive, n = 25 (34.2%) p
Gender, female (%) 8/48 (16.7%) 7/25 (28.0%) 0.20
Recipient Age (median, range), years 55 (30–69) 59 (41–66) 0.36
Follow up (median, range), months 39.5 (2.0–91.2) 20.7 (0.6–102.9) 0.78
Time of ERC (median, range), months 3.5 (0.3–73.6) 2.4 (0.3–22.1) 0.38
Donor age (median, range), years 60 (21–88) 61 (27–82) 0.65
eMELD at LT, points (mean ± SD) 27.6 (± 5.3) 27.3 (± 4.9) 0.87
labMELD at LT, points (mean ± SD) 16.4 (± 9.5) 22.5 (± 12.2) 0.02
Cold ischemia time,hours, (mean ± SD) 9.8 (± 2.6) 10.4 (± 2.7) 0.37
AS 25/48 (48.1%) 9/25 (36.0%) 0.17
NAS 20/48 (41.7%) 17/25 (68.0%) 0.03
Acute rejection 8/48 (16.6%) 11/25 (44.0%) 0.01
CMV positivity in bile 10/48 (20.8%) 3/23 (13.0%) 0.33
HHV-7 positivity in bile 6/48 (12.5%) 9/25 (36.0%) 0.02
HHV-6 positivity in liver biopsy 4/33 (12.1%) 4/20 (20.0%) 0.30
HHV-6 positivity in serum 0/30 (0%) 1/11 (9.1%) 0.29
AP (U/ml, SD) 194.1 (± 125.4) 195.6 (± 153.8) 0.96
Bilirubin (mg/ml, SD) 6.2 (± 9.3) 7.6 (± 8.8) 0.52
AST (U/ml, SD) 100.9 (± 102.9) 144.9 (± 192.5) 0.21
Leukocytes (cells/nl, SD) 6.2 (± 2.7) 7.7 (± 5.5) 0.12
AP: alkaline phosphatase, AS: anastomotic biliary stricture, AST: aspartate aminotransferase, CMV: cytomegalovirus, eMELD: exceptional model of end-stage liver
disease, ERC: endoscopic retrograde cholangiopancreatography, HHV: human herpesvirus, LT: liver transplantation,labMELD: laboratory model of end-stage liver
disease, NAS: non-anastomotic biliary stricture, SD: standard deviation
Table 5 Valganciclovir and herpesvirus reactivation. Data is given as number (%)
LT recipients (n = 71)
Valganciclovir prophylaxis (n = 34) No Valganciclovir prophylaxis (n = 37) p
EBV positive 3/34 (8.9%) 9/37 (24.3%) 0.07
CMV positive 3/33 (9.1%) 10/36 (27.8%) 0.04
HHV-6 positive 13/34 (38.2%) 10/37 (27%) 0.25
HHV-7 positive 6/34 (17.6%) 7/37 (18.9%) 0.9
CMV cytomegalovirus, EBV Epstein-Barr virus, HHV human herpesvirus, HSV herpes simplex virus, LT liver transplantation, VZV varicella-zoster virus
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risk factors for mortality and associated with early allo-
graft loss, which were evenly distributed in our study.
Increased recipient morbidity at time of transplant-
ation likewise seems to play a role for biliary HHV-6 in-
fections. We recorded labMELD score at transplantation
as a surrogate marker for recipient morbidity at trans-
plantation [31]. Patients positive for HHV-6 in bile had a
higher median labMELD (16.4 vs. 22.5, p = 0.02, Table 4)
but not a higher eMELD score at LT. Patients with a
higher labMELD score at the time of transplantation
presented more severe hepatic and renal impairment.
This precondition might predispose patients to oppor-
tunistic infections and, in our study, might in part ex-
plain the increased prevalence of herpesvirus infections.
The association of HHV-6 with graft complications and
reduced survival poses the important question of
A B
C D
Fig. 2 Retransplantation free survival after ERC according to herpesvirus positivity in bile. Comparison of retransplantation free survival after ERC
according to herpesvirus positivity in bile, comparison with log-rank. A Human herpesvirus 6 (HHV-6) B Human Herpesvirus 7 (HHV-7) C
Cytomegalovirus (CMV) D Epstein-Barr-Virus (EBV)
Table 6 Uni- and multivariate analysis of risk factors for graft loss or death
Univariate Multivariate
Hazard ratio (95% CI) p Hazard ratio (95% CI) p
HSV-1 positivity (bile) 2.34 (0.70–7,80) 0.17
HSV-1 positivity (serum) 0.43 (0.06–3.49) 0.39
EBV positivity (bile) 0.82 (0.28–2.38) 0.72
EBV positivity (serum) 2.18 (0.47–10.02) 0.32
CMV positivity (bile) 0.21 (0.29–1.58) 0.13
HHV-6 positivity (bile) 2.72 (1.25–5.90) 0.01 2.15 (0.94–4.95) 0.07
HHV-6 positivity (liver biopsy) 1.02 (0.30–3.46) 0.98
HHV-7 positivity (bile) 2.57 (1.14–5.78) 0.02 2.03 (0.81–5.12) 0.13
Valganciclovir at time of ERC 1.78 (0.97–3.26) 0.07 0.99 (0.48–2.07) 0.87
Time between LT and ERC [months] 0.93 (0.86–1.01) 0.08 0.94 (0.79–1.12) 0.27
NAS vs. AS/control 1.74 (0.99–3.05) 0.05 0.94 (0.79–1.12) 0.47
Recipient age, years 1.02 (0.97–1.07) 0.49
Donor age, years 1.02 (0.99–1.04) 0.18
MELD score at LT 0.94 (0.81–1.01) 0.12
Cold ischemia time 0.96 (0.83–1.11) 0.39
AS, anastomotic biliary stricture, CMV cytomegalovirus, EBV Epstein-Barr virus, HHV human herpesvirus, ERC endoscopic retrograde cholangiopancreatography, HSV
herpes simplex virus, LT liver transplantation, MELD model of end-stage liver disease, NAS non-anastomotic biliary stricture, VZV varicella-zoster virus
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possible prevention of HHV-6 reactivation/infection.
Interestingly, valganciclovir prophylaxis did not reduce
the incidence of HHV-6 prevalence nor the mean viral
count in bile (38.2% vs. 27%, p = 0.25, Table 5). This
might be due to a lower responsiveness of HHV-6 and
HHV-7 than CMV to valganciclovir or ganciclovir treat-
ment [32]. In a study by Humar et al. of CMV, HHV-6
and HHV-7 coinfected patients, valganciclovir treatment
did reduce the CMV but not the HHV-6 and HHV-7
viral load [32]. Consistent in our study CMV prophylaxis
was sufficient in our patients to prevent CMV infection.
This might explain why in our study CMV in bile was
not related to NAS, contrasting with prior data pub-
lished by our group [4]. In the current study, bile re-
trieval was undertaken early after LT while many
patients (47.8%) were under CMV prophylaxis. When
excluding patients on prophylactic therapy, there was a
numerical though statistically insignificant higher preva-
lence of non-anastomotic strictures in patients who
tested positive for CMV in bile (50% vs. 33%, ns).
Two important findings conclude our study. The first
is the striking discrepancy of herpesvirus detection of
the different compartments (bile, serum, tissue). Cur-
rently, blood serum is used for routine HHV-6 detection;
indeed biliary samples might be more sensitive and spe-
cific for HHV-6 detection in the liver allograft. This
finding is not limited to herpesviruses but might extend
to all DNA-viruses and bacteria. We thus hypothesize
that testing biliary fluid might mirror local infective pro-
cesses of the hepatobiliary compartment with a higher
sensitivity than serum or biopsy specimen. The second
important finding is the correlation between locoregio-
nal HHV-6 (and possibly CMV in the later course) de-
tection and severe liver allograft complications. We
further hypothesize that routine CMV prophylaxis with
valganciclovir is not sufficient to prevent HHV-6 (and
HHV-7) infection, which raises important questions for
clinical practice [33, 34].
Our study however poses several important limita-
tions. HHV-6 positivity in bile did not significantly cor-
relate with positivity in the liver biopsy. Even samples
with very high virus counts in bile that where taken on
subsequent days to the liver biopsy showed no virus
amplification in the biopsy tissue. It could be possible,
that the liver biopsy was non representative of the donor
organ. The focal distribution of HHV-6 in infected liver
tissue is not known. The design of the study was a retro-
spective case-control study wherein different cohorts
were randomly selected from a tissue and fluid biobank.
Concordant biopsy, serum and bile samples were not al-
ways available, and when they were available, they were
not always taken on the same day.
The methods for DNA detection were not established
for biliary fluids, and stability data on viral DNA in
biliary fluid is lacking. Furthermore, viral loads for
HHV-6 were low. Only 4 out of 25 patients had viral
loads > 1000 copies/ml, the threshold for consideration
as an active HHV-6 infection in serum samples [35].
While this finding could reflect a high percentage of la-
tent infection and explain why viral DNA in those cases
could not be detected in serum samples from the same
recipients, this could also be due to DNA degradation in
our bile samples. Our study warrants further exploration
in a prospective experimental setting. If confirmed, treat-
ment of occult HHV-6 and HHV-7 infection in cases of
sustained and progressive biliary damage after LT might
lead to a reduced risk of graft loss and need for re-LT.
Further understanding of the role of non-CMV beta-
herpesviruses in LT might also affect recommendations
for the routine use of valganciclovir in the initial months
after LT.
Conclusion
The present study shows that CMV, EBV and HHV-6
and -7 are highly prevalent in biliary fluid. Overall beta-
herpesvirus detection was more frequent in bile than in
liver biopsy or serum. HHV-6 is associated with biliary
complications after LT. Further studies are needed to as-
sess the potential connection of HHV-6 detection in bile
and biliary complications after LT and the general value
of routine viral diagnostics in bile compared to serum
and liver biopsy.
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